Patrick John Finn - 17 Feb 2026 Form 4 Insider Report for Twist Bioscience Corp (TWST)

Role
President and COO
Signature
/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn
Issuer symbol
TWST
Transactions as of
17 Feb 2026
Net transactions value
-$2,276,576
Form type
4
Filing time
19 Feb 2026, 16:05:19 UTC
Previous filing
17 Feb 2026
Next filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Finn Patrick John President and COO C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO /s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn 19 Feb 2026 0001755970

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TWST Common Stock Options Exercise $424,723 +18,205 +5.9% $23.33 324,455 17 Feb 2026 Direct F1
transaction TWST Common Stock Options Exercise $861,118 +32,300 +10% $26.66 356,755 17 Feb 2026 Direct F1
transaction TWST Common Stock Sale $1,099,916 -21,858 -6.1% $50.32 334,897 17 Feb 2026 Direct F1, F2
transaction TWST Common Stock Sale $854,445 -16,616 -5% $51.42 318,281 17 Feb 2026 Direct F1, F3
transaction TWST Common Stock Sale $1,419,993 -26,952 -8.5% $52.69 291,329 17 Feb 2026 Direct F1, F4
transaction TWST Common Stock Sale $188,063 -3,541 -1.2% $53.11 287,788 17 Feb 2026 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TWST Stock Option (right to buy) Options Exercise $0 -32,300 -100% $0.000000 0 17 Feb 2026 Common Stock 32,300 $26.66 Direct F1, F6
transaction TWST Stock Option (right to buy) Options Exercise $0 -18,205 -100% $0.000000 0 17 Feb 2026 Common Stock 18,205 $23.33 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025.
F2 Represents the weighted average sales price per share. The shares sold at prices ranging from $50.00 to $50.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 Represents the weighted average sales price per share. The shares sold at prices ranging from $51.00 to $51.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4 Represents the weighted average sales price per share. The shares sold at prices ranging from $52.00 to $52.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5 Represents the weighted average sales price per share. The shares sold at prices ranging from $53.01 to $53.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F6 The option is immediately exercisable. 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F7 The option is immediately exercisable. 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date.